Home Tags Drug Development

Drug Development Related Content

THC in CBD, EUMCA

EUMCA: Limit of 0.2% THC in CBD products should not change

Chair of the European Medicinal Cannabis Association (EUMCA) issues warning that raising limit for THC in CBD to 0.3% will risk patient safety.
access to medicinal cannabis, trevor jones

The EUMCA: Pioneering access to medicinal cannabis

Professor Trevor Jones, Chair at the European Medicinal Cannabis Association, speaks to Nishat about their plans for EU patient access to medicinal cannabis.
biochemistry

How does research in biochemistry fit into the wider goals of the NIH?

Open Access Government looks into the National Institute of General Medical Sciences (NIGMS)’s Biochemistry and Bio-related Chemistry Branch, and its current research areas and priorities.
vision disorders

How can biomaterials-based technologies treat vision disorders?

Professor Heather Sheardown, leader of Innovation Hub C20/20, discusses their research, innovation, and development of new biomaterials-based technologies to treat a variety of disorders in the eye.
cytochromes p450

Cytochromes P450: Chemistry for drugs, metabolism, and beyond

Joseph Najjar and Andrew K. Udit, PhD from the Department of Chemistry at Occidental College enlighten us on the importance of Cytochromes P450 in medicine and industry.
Gyrase and topoisomerase IV

Gyrase and topoisomerase IV: Repurposing old targets for new antibacterials

Neil Osheroff from the Vanderbilt University School of Medicine is working to overcome drug resistance and revitalise the use of established targets for antibacterial agents, as we discover here.
imaging biomarkers

Oncology: Imaging biomarkers and the Alberta Radiopharmaceutical Collaboration

Dr Frank Wuest, Professor at Department of Oncology - University of Alberta, sheds light on the imaging biomarkers and the Alberta Radiopharmaceutical Collaboration in this special oncology focus.
influenza virus

Enduring research: The constant threat of influenza virus outbreaks

Here, experts Stephan Pleschka, Oliver Planz and Stephan Ludwig walk us through the constant threat of influenza virus outbreaks and the benefit of enduring research in antiviral drug development.
treat COVID-19, drug

Existing drugs should be used to treat COVID-19 instead of vaccine

Researchers say we should repurpose existing drugs, which would be faster than waiting for a "magic bullet" vaccine to treat COVID-19.
SARS-CoV-2

Scientists design novel chemical compounds using AI to combat SARS-CoV-2

Scientists at TCS designed novel chemical compounds using AI that can inhibit the 3CL protease of SARS-CoV-2, which is responsible for viral replication. Ananth Krishnan, Chief Technology Office, TCS, discusses the research here.
curing hepatitis C

Drugs used for curing hepatitis C might also help against COVID-19

Several drugs used for curing hepatitis C have been identified as potential candidates to treat COVID-19, according to research conducted using the MOGON II supercomputer at Johannes Gutenberg University Mainz.
antibiotic future

Radical change is required to ensure an antibiotic future

Daniel Berman, Head of Global Health, Nesta Challenges, highlights the need for radical change in how innovation is funded and prioritised to ensure an antibiotic future given AMR is still climbing, even though behaviours are changing.
drug policy reform, psychedelic

The Psychedelic Renaissance and the importance of drug policy reform

In the view of Amanda Feilding, Founder of the Beckley Foundation, “Psychedelics are unique pharmacological compounds that hold the promise of a profound paradigm shift in psychiatry.” Here, we learn about the Psychedelic Renaissance and the importance of drug policy reform.
Beckley Foundation

Beckley Foundation – Changing minds, altering perceptions

The Beckley Foundation initiates and supports research into psychedelic compounds to better understand their effects and medical applications.
reduce drug costs, carbon emissions

‘Green’ asthma inhalers would reduce drug costs

Researchers at Cambridge have found that 'green' asthma inhalers would both reduce carbon emissions and reduce drug costs.
Medical devices policy

Medical devices policy: Japan’s Ministry of Health, Labour and Welfare

Here, we look at medical devices policy of Japan’s Ministry of Health, Labour and Welfare. The Ministry now has Katsunobu Katō in place, who very recently replaced Nemoto Takumi as the Minister of Health, Labour and Welfare in the country.
your chemistry

Getting your chemistry right

Prof Colin J Suckling OBE DSc FRSE from the Department of Pure & Applied Chemistry, at University of Strathclyde, explains the importance of getting your chemistry right.
regulation of hepatitis B

Multi-step regulation of hepatitis B virus entry

Koichi Watashi, Senior Researcher from the National Institute of Infectious Diseases, Japan, explores the trick for cell invasion in reaching regulation of hepatitis B entry.
non communicable diseases in africa, endocrine disruptors

Endocrine disruptors and non-communicable diseases in Africa

Chiara Frazzoli and Alberto Mantovani from Istituto Superiore di Sanità share their insights into endocrine disruptors and non-communicable diseases in Africa, in collaboration with NOODLES Alliance Network.
antimicrobial adhesive, healthcare-associated infection

FLEXPOL: An antimicrobial adhesive film

The EU-funded project FLEXPOL (GA number 721062) offers an affordable approach to prohibit the spread of bacteria and healthcare-associated infections using cost-effective and sustainable film products.

Follow Open Access Government